HomeAI · summaries
Storia in 3 fonti
Kelun scores sac-TMT win in first-line NSCLC population missing from Merck’s massive phase 3 program
The clinical blueprint for Merck & Co.’s prized TROP2-directed antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), could add a missing piece thanks to a landmark achieved by its partner | The clinical blueprint for Merck & Co.’s prized TROP2-directed antibody-drug conjugate, sac-TMT, could add a missing piece thanks to a landmark achieved by its partner, Kelun-Biotech.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma
The FDA has approved a new | The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become a new standard-of-care for patients…
- ·
morningstar.com
Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for…
